SAN DIEGO, Feb. 26, 2004 (PRIMEZONE) -- Sagient Research Systems (OTCBB:PCSR), a leading publisher of independent research for the financial services and institutional investment communities, today announced that it has expanded its healthcare coverage and added two new analysts focused on the biotechnology sector.
Sagient's Healthcare Group has expanded its research coverage in the areas of oncology, cardiology, and systematic disorders. It now provides full coverage on 24 companies and 350 drugs in over 700 clinical indications. In addition, Sagient monitors over 200 upcoming catalysts that could effect valuations of biotechnology companies, looking to identify investment opportunities in the biotech and pharmaceutical industry by assessing the relative strength of companies' clinical drug pipelines, and by highlighting potential future catalysts that could dramatically impact those pipelines.
In addition, Sagient Research has added two new healthcare analysts to its team.
Rahul Jasuja, Ph.D., has joined the firm as a Senior Healthcare Analyst. Prior to joining Sagient Research, Dr. Jasuja was the Senior Biotechnology Analyst with SOMA Partners LLC (Techvest LLC) and a Senior Biotechnology Analyst at Rodman & Renshaw. Dr. Jasuja earned a Ph.D. in Immunology from the Tufts University School of Medicine and performed extensive post-doctoral and doctoral research at Harvard Medical School in immunology and inflammation.
Scott Andryski, Ph.D. has joined the firm as a Healthcare Analyst. Dr. Andryski has extensive clinical experience, including research work at the Scripps Research Institute in La Jolla, Calif. and at the Lawrence National Laboratory in Berkeley, Calif. Dr. Andryski earned his Ph.D. in Chemistry from the University of California at Berkeley.
"We welcome Rahul and Scott to our healthcare team," said Brian M. Overstreet, president and CEO of Sagient Research. "We believe that they bring a great mix of analytical and clinical experience that will be invaluable to our institutional client base. Our coverage of the biotechnology sector has been a main driver of the company's growth over the past year and we remain committed to providing unique, proprietary, and value-added research in this exciting investment field, identifying companies with promising clinical programs early."
Sagient's healthcare coverage is presented through its BioMedTracker service at www.biomedtracker.com. BioMedTracker is an institutional research service that identifies investment opportunities in the biotech and pharmaceutical industry by assessing the relative strength of companies' clinical drug pipelines and by highlighting potential future catalysts that could dramatically impact those pipelines. The BioMedTracker team looks at clinical trial data and the regulatory history of each drug under coverage to assess its overall likelihood of approval by the FDA. Each Impact Event that affects the likelihood of approval of the drug is transparent so that subscribers can see the rationale for the analysis. Drugs are further analyzed for their commercial potential and presented in a 10-year Revenue Detail model for the U.S., Europe and Japan. Dates of approval, target patient populations, annual wholesale prices, market penetration, and other factors are estimated in formulating these revenue projections
About Sagient Research Systems
PCS Research Technology, Inc. d/b/a Sagient Research Systems is a publisher of independent research. We develop, produce, and sell proprietary research products to mutual funds, hedge funds, and investment banks. Our business strategy is to continue to leverage our development, technology, and marketing expertise to solidify our position as a leading provider of independent research to the financial services and institutional investment communities. For more information, please visit the Sagient Research Systems website at www.sagientresearch.com.
Safe Harbor Statement
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.